证券代码：301206 证券简称：三元生物 公告编号：2025-084 山东三元生物科技股份有限公司 关于召开 2025 年第五次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东会届次：2025 年第五次临时股东会 （二）股东会的召集人：董事会 （三）本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公 司章程》的有关规定。 （四）会议时间： 1、现场会议时间：2025 年 11 月 12 日 15:00 2、网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2025 年 11 月 12 日 9:15 至 15:00 的任意时间。 （五）会议的召开方式：现场表决与网络投票相结合。 （六）会议的股权 ...

山东三元生物科技股份有限公司（以下简称"公司"）第五届董事会第九次 会议于 2025 年 10 月 24 日上午 9:30 在公司会议室以现场+视频方式召开。会议 通知于 10 月 18 日以书面、电话方式通知到各位董事，本次会议应到董事 9 人， 实到董事 9 人，会议由董事长聂在建主持，董事会秘书、财务总监列席本次会议。 会议的召集、召开和表决程序符合《公司法》和《公司章程》的有关规定，所作 决议合法有效。 证券代码：301206 证券简称：三元生物 公告编号：2025-081 山东三元生物科技股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 二、议案审议情况 本次会议以记名投票表决方式表决通过如下议案： （一）审议通过《2025 年第三季度报告》； 公司依据相关规定要求编制了 2025 年第三季度报告。 经审核，董事会认为：《2025 年第三季度报告》的内容公允地反映了公司 2025 年第三季度的财务状况和经营成果，报告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。其编制 ...

关于 2025 年前三季度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：301206 证券简称：三元生物 公告编号：2025-083 山东三元生物科技股份有限公司 公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第 9.4 条 相关规定的可能被实施其他风险警示情形。 一、审议程序 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 18 日召开了第五届董事会审计委员会第五次会议、于 2025 年 10 月 24 日召开了第 五届董事会第九次会议，上述会议审议通过了《关于 2025 年前三季度利润分配 预案的议案》，该议案尚需提交公司 2025 年第五次临时股东会审议。 （一）董事会审计委员会审议情况 公司于 2025 年 10 月 18 日召开了第五届董事会审计委员会第五次会议，会 议审议通过了《关于 2025 年前三季度利润分配预案的议案》。审计委员会认为： 公司 2025 年前三季度利润分配预案符合《公司法》《上市公司监管指引第 3 号— —上市公司现金分红》《公司章程》及《未来 ...

山东三元生物科技股份有限公司 2025 年第三季度报告 证券代码：301206 证券简称：三元生物 公告编号：2025-080 山东三元生物科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： □是 否 一、主要财务数据 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 会计差错更正 | | | | | 本报告期 | | | | 年初至报告 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 本报告期 | 上年同期 | | 比上年同 | 年初至报 | 上年同期 | | 期末比上年 | | | | | ...

10月23日，三元生物大宗交易成交20万股，成交额552.4万元，占当日总成交额的14.59%，成交价27.62元，较市场收盘价 27.9元折价1%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 (万元) | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | | | | 2025-10-23 | 301206 | 三元生物 | 27.62 | 20.00 | 552.40 华泰证券股份有限 | 中信建投证券股份 | | | | | | | 公司南京清凉门大 | 有限公司淄博政通 | | | | | | | 街证券营业部 | 路证券营业部 | ...

Core Insights - San Yuan Bio's stock rose by 1.07% to close at 28.29 yuan, with a significant block trade of 200,000 shares amounting to 5.602 million yuan [1] - The first transaction occurred at a price of 28.01 yuan for 200,000 shares, reflecting a premium rate of -0.99%, with Huatai Securities as the buyer and CITIC Securities as the seller [1] - Over the past three months, San Yuan Bio has recorded 12 block trades totaling 98.16 million yuan, while the stock has seen a cumulative increase of 0.89% over the last five trading days, with a net outflow of 5.6411 million yuan from major funds [1]

Core Viewpoint - The article discusses the emerging market for D-Allulose, a new sugar substitute approved for use in China, highlighting its potential applications and the industry's response to its commercialization [3][5][10]. Group 1: Market Potential and Demand - D-Allulose is recognized as a "new generation sugar substitute" with a sweetness level of 70% compared to sucrose and low caloric content, making it a promising alternative for the food industry [5][12]. - The global market for D-Allulose is projected to reach $14.77 million in 2024, with a compound annual growth rate (CAGR) exceeding 14% from 2025 to 2034 [6]. - The "Healthy China Action (2019-2030)" initiative aims to limit daily added sugar intake to 25 grams per person, increasing the demand for safer and higher-quality sugar substitutes [3][5]. Group 2: Production and Supply Chain - D-Allulose can be produced through two main methods: biological fermentation using E. coli and enzyme-catalyzed conversion, with the latter being more commonly adopted due to lower initial investment requirements [8][9]. - Major companies like COFCO and Baolingbao are ramping up production capabilities, with Baolingbao planning to reach an annual production capacity of approximately 30,000 tons by 2026 [9][12]. - The production process is currently limited by the availability of enzyme preparations, which are crucial for D-Allulose production [9][10]. Group 3: Industry Response and Challenges - Downstream companies, including Wahaha and Mengniu, are interested in testing D-Allulose in their products, but large-scale application is still in the research and testing phase [11][12]. - The cost of D-Allulose remains a significant barrier, with current prices ranging from 20,000 to 24,000 yuan per ton, compared to around 10,000 yuan per ton for erythritol [13][14]. - Concerns about potential overcapacity in the market exist, as seen with erythritol, which experienced a price drop due to oversupply [14][15]. Group 4: Future Outlook - The industry outlook for D-Allulose remains optimistic, with expectations that production costs will decrease as capacity increases [15]. - Key factors for market success include continuous technological innovation, cost control, and the establishment of a complete industrial ecosystem [15].

Core Insights - D-Allulose, a new natural sweetener, has been approved for commercial use in China, with significant industry interest and potential applications in food products [1][2][4] Industry Overview - The approval of D-Allulose aligns with the goal of reducing daily sugar intake to 25 grams per person by 2030 as outlined in the Healthy China Action Plan [1] - D-Allulose is recognized for its low-calorie content, being approximately one-tenth the energy of sucrose, and its potential benefits in managing obesity and type 2 diabetes [2] Market Potential - The global market for D-Allulose is projected to reach $14.77 million in 2024, with a compound annual growth rate (CAGR) exceeding 14% from 2025 to 2034 [3] Production and Technology - D-Allulose can be produced through two main methods: fermentation using E. coli and enzyme-catalyzed conversion [4] - Companies like Zhongliang Group have developed proprietary enzymes for D-Allulose production, while others rely on partnerships with research institutions for enzyme sourcing [5][11] Industry Players - Major companies such as Baolingbao, Sanyuan Biotech, and Dongxiao Biotech are expanding their D-Allulose production capabilities, with Baolingbao aiming for an annual capacity of 30,000 tons by 2026 [6][8] - Downstream companies, including Wahaha and Mengniu, are showing interest in testing D-Allulose in their products, although large-scale adoption is still in the experimental phase [7][8] Cost Considerations - The current price of D-Allulose ranges from 20,000 to 24,000 yuan per ton, significantly higher than erythritol, which is around 10,000 yuan per ton [9] - Companies are exploring ways to reduce costs through scale and customized formulations to enhance competitiveness [9][11] Challenges and Risks - The industry faces potential overcapacity risks, as seen with erythritol, which previously experienced a price crash due to oversupply [10] - The successful market penetration of D-Allulose will depend on continuous innovation, cost control, and the establishment of a comprehensive industry ecosystem [11]

Core Insights - D-Allulose, a new low-GI sweetener, has been approved for commercial use in China, with significant industry interest and potential applications in food products [1][2][4] - The global market for D-Allulose is projected to reach $14.77 million in 2024, with a compound annual growth rate (CAGR) exceeding 14% from 2025 to 2034 [3] Industry Overview - The approval of D-Allulose aligns with the "Healthy China Action (2019-2030)" initiative, which aims to limit daily added sugar intake to 25 grams per person by 2030 [1] - D-Allulose is recognized for its sugar-like taste, low caloric content (1.67 kJ/g or 0.4 kcal/g), and potential health benefits, including no impact on blood lipids or uric acid levels [2] Production and Supply Chain - D-Allulose can be produced through two main methods: fermentation using E. coli and enzyme-catalyzed conversion [4][5] - Companies like COFCO and Zhongda Hengyuan are actively developing production capabilities, with COFCO utilizing self-developed enzymes for production [5] - The production process is complex, with a need for advanced technology and significant initial investment, leading to a competitive landscape among producers [4][5] Market Dynamics - Downstream companies, including Wahaha and Mengniu, are showing interest in D-Allulose, but large-scale application is still in the testing phase [6][7] - The current cost of D-Allulose is significantly higher than other sweeteners, with prices ranging from 20,000 to 24,000 yuan per ton, compared to around 10,000 yuan per ton for erythritol [8] Future Prospects - The industry is optimistic about D-Allulose's potential, citing its broader application scenarios compared to erythritol, particularly in products sensitive to crystallization [10] - Key factors for market success include ongoing technological innovation, cost control, and the establishment of a complete industry ecosystem [10]

Core Insights - Shandong Province's Development and Reform Commission has promoted the case of Binzhou City as a typical example of fostering venture capital development, highlighting its effective implementation of national and provincial policies [1] - In 2024, Binzhou's venture capital assessment ranked third in the province, with a cumulative investment amount increasing by 39.1% year-on-year [1] Group 1: Government Guidance - The city has established a "3+3+N" industrial development fund matrix, which includes three guiding mother funds, three functional funds, and multiple sub-funds to support the "5210N" industrial cluster [1] - A municipal venture capital reward fund has been set up, integrating venture capital into the high-quality development assessment of counties, creating a collaborative work framework [1] Group 2: Chain-based Cultivation - The integration of industrial chains, innovation chains, and capital chains is emphasized, with a focus on creating an "one cluster, one fund" investment layout [2] - A special industry fund group with a total scale exceeding 2 billion yuan has been established to invest in specialized, innovative, and industry-leading small and medium-sized enterprises [2] - The city has attracted 2.8 billion yuan from external venture capital funds, successfully bringing in leading technology projects to promote the integration of production, education, and research [2] Group 3: Project Carrier - A quality project reserve library has been established, dynamically storing 100 enterprises, with 65 projects successfully landed, including several technology companies that have gone public with venture capital support [3] - Comprehensive services such as financing connections, resource guarantees, and training sessions have been provided, with over 20 training sessions conducted, covering more than 700 enterprise leaders and financial professionals [3]